We are live on ! Find out more
BSEM icon

BioStem Technologies

0.6351 USD
-0.0724
10.23%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
0.6271
-0.0080
1.26%
1 day
-10.23%
5 days
-47.07%
1 month
-61.27%
3 months
-82.74%
6 months
-84.47%
Year to date
-84.47%
1 year
-84.47%
5 years
-84.47%
10 years
-84.47%
 

About: BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.

Employees: 2

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 8.3%
Neutral 91.7%
Negative 0%
Neutral
Seeking Alpha
8 days ago
BioStem Technologies, Inc. (BSEM) Q3 2026 Earnings Call Transcript
BioStem Technologies, Inc. (BSEM) Q3 2026 Earnings Call Transcript
BioStem Technologies, Inc. (BSEM) Q3 2026 Earnings Call Transcript
Neutral
Zacks Investment Research
8 days ago
BioStem Technologies, Inc. (BSEM) Reports Q3 Loss, Beats Revenue Estimates
BioStem Technologies, Inc. (BSEM) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to earnings of $0.03 per share a year ago.
BioStem Technologies, Inc. (BSEM) Reports Q3 Loss, Beats Revenue Estimates
Neutral
GlobeNewsWire
8 days ago
BioStem Technologies Reports Third Quarter 2026 Financial Results; Grows Hospital Revenue for Second Consecutive Quarter as Customers Expand Use of Portfolio
Hospital revenue grew sequentially to $6.8 million; customers purchasing two or more product lines up 14% from the second quarter In-house production of Neox® and Clarix® on track to begin in the first half of 2027 Raises full-year 2026 revenue guidance POMPANO BEACH, Fla., Nov. 12, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today reported financial results for the third quarter ended September 30, 2026 and raised full year 2026 revenue guidance.
BioStem Technologies Reports Third Quarter 2026 Financial Results; Grows Hospital Revenue for Second Consecutive Quarter as Customers Expand Use of Portfolio
Neutral
GlobeNewsWire
22 days ago
BioStem Technologies to Host Third Quarter 2026 Financial Results Conference Call on November 12, 2026
POMPANO BEACH, Fla., Oct. 29, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announces it will release its third quarter 2026 financial results on Thursday, November 12, 2026, and will host a conference call and webcast at 4:30 PM ET.
BioStem Technologies to Host Third Quarter 2026 Financial Results Conference Call on November 12, 2026
Neutral
GlobeNewsWire
1 month ago
BioStem Technologies' CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options
POMPANO BEACH, Fla., Oct. 08, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced its Chair and Chief Executive Officer, Jason Matuszewski, and Chief Operating Officer, Andrew Van Vurst, each exercised a portion of their outstanding options to purchase 250,000 shares of BioStem common stock at an exercise price of $2.00 per share, for a total of 500,000 shares and an aggregate purchase price of approximately $1 million.
BioStem Technologies' CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options
Neutral
GlobeNewsWire
1 month ago
BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio
POMPANO BEACH, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that the United States Patent and Trademark Office (USPTO) has issued one patent and three notices of allowance for additional patent applications and the Mexican Institute of Industrial Property (IMPI) has issued one notice of allowance for additional patent applications.
BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio
Neutral
GlobeNewsWire
1 month ago
BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
POMPANO BEACH, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that it has entered into definitive agreements for the issuance and sale of 735,296 shares of the Company's common stock, Series A warrants to purchase up to an aggregate of 735,296 shares of common stock and Series B warrants to purchase up to an aggregate of 735,296 shares of common stock, at a purchase price of $4.08 per share and associated warrants in a private placement priced at-the-market under Nasdaq rules.
BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Neutral
GlobeNewsWire
2 months ago
Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform
West Palm Beach, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform.
Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform
Neutral
GlobeNewsWire
2 months ago
BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility
POMPANO BEACH, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a $40 million Committed Equity Facility (the “CEF”) with Roth Principal Investments, LLC (“Roth”), an affiliate of CR Financial Holdings, Inc., the holding company for Roth Capital Partners.
BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility
Neutral
GlobeNewsWire
2 months ago
BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier
POMPANO BEACH, Fla., Sept. 04, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that VENDAJE® and VENDAJE AC® have been added to the Company's existing contracts with Vizient, Inc. and Premier, Inc., two of the nation's largest Group Purchasing Organizations (GPOs).
BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier
Price charts implemented using Lightweight Charts™